San Diego, United States
ARS Pharmaceuticals, Inc., founded in 2015, is a pioneering company in the Biopharma sector headquartered in the United States. The company is focused on transforming how severe allergic reactions are treated by introducing a revolutionary needle-free epinephrine nasal spray. Their tagline, "Revolutionizing treatment for severe allergic reactions with the development of a needle-free epinephrine nasal spray," encapsulates their mission. ARS Pharma addresses common challenges such as needle-related risks and device portability, providing an empowering solution for patients and caregivers.
In September 2025, the company secured a Debt Financing investment from notable investors OMERS and RA Capital Management, underscoring confidence in their innovative approach. As a leader in the intersection of Health Care and Pharmaceutical industries, ARS Pharmaceuticals is well-positioned to capture significant market share by offering a safer, accessible alternative for allergic reaction management.
